OnKure Therapeutics Inc. (OKUR)
OnKure Therapeutics Statistics
Share Statistics
OnKure Therapeutics has 13.44M shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | 13.44M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | 377 |
| FTD / Avg. Volume | 0.76% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -2.18 and the forward PE ratio is null. OnKure Therapeutics's PEG ratio is -0.04.
| PE Ratio | -2.18 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | 1.1 |
| P/FCF Ratio | -2.24 |
| PEG Ratio | -0.04 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for OnKure Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.73, with a Debt / Equity ratio of 0.01.
| Current Ratio | 10.73 |
| Quick Ratio | 10.73 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | -0.02 |
| Debt / FCF | -0.02 |
| Interest Coverage | -181.29 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1.15M |
| Employee Count | 46 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -85.38% in the last 52 weeks. The beta is 0.35, so OnKure Therapeutics's price volatility has been higher than the market average.
| Beta | 0.35 |
| 52-Week Price Change | -85.38% |
| 50-Day Moving Average | 4.13 |
| 200-Day Moving Average | 10.91 |
| Relative Strength Index (RSI) | 19.76 |
| Average Volume (20 Days) | 49.86K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -54.39M |
| Net Income | -52.67M |
| EBITDA | -51.71M |
| EBIT | -52.37M |
| Earnings Per Share (EPS) | -3.95 |
Balance Sheet
The company has 110.76M in cash and 1.08M in debt, giving a net cash position of 109.68M.
| Cash & Cash Equivalents | 110.76M |
| Total Debt | 1.08M |
| Net Cash | 109.68M |
| Retained Earnings | -154.72M |
| Total Assets | 114.91M |
| Working Capital | 102.47M |
Cash Flow
In the last 12 months, operating cash flow was -51.12M and capital expenditures -52K, giving a free cash flow of -51.17M.
| Operating Cash Flow | -51.12M |
| Capital Expenditures | -52K |
| Free Cash Flow | -51.17M |
| FCF Per Share | -3.84 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
OKUR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for OKUR is $32.5, which is 1200% higher than the current price. The consensus rating is "Buy".
| Price Target | $32.5 |
| Price Target Difference | 1200% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Stock Splits
The last stock split was on Oct 7, 2024. It was a backward split with a ratio of 1:10.
| Last Split Date | Oct 7, 2024 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | -0.69 |
| Piotroski F-Score | 2 |